CN110498845B - Peste des petits ruminants diagnostic kit - Google Patents
Peste des petits ruminants diagnostic kit Download PDFInfo
- Publication number
- CN110498845B CN110498845B CN201810480848.7A CN201810480848A CN110498845B CN 110498845 B CN110498845 B CN 110498845B CN 201810480848 A CN201810480848 A CN 201810480848A CN 110498845 B CN110498845 B CN 110498845B
- Authority
- CN
- China
- Prior art keywords
- seq
- des petits
- peste des
- petits ruminants
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G01N2333/12—Mumps virus; Measles virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a diagnostic kit for Peste des petits ruminants. The detection kit comprises a substrate and a specific polypeptide or a specific polypeptide combination independently connected to the substrate.
Description
Technical Field
The invention mainly relates to a diagnostic kit and a diagnostic method for animals. In particular, the invention relates to a kit for detecting the presence or absence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject.
Background
The Pestedespetits ruminants (PPR) is an acute, violent and contact infectious disease caused by Pestedespetits ruminants virus (PPRV), has great threat to animals such as goats, sheep, white-tailed deer, wild gazelle, Tibetan antelope and the like due to high morbidity and mortality, is a recognized violent infectious disease in the world, and is classified as an animal infectious disease in China. In 1942, after the first report of Peste des petits ruminants by Cottdifa, West Africa, most countries in Africa have successively reported the occurrence of this disease. In recent years, Peste des petits ruminants have seen a trend toward further spread. In 2007, the disease is firstly discovered in China to be transmitted from India to local areas of Tibet of China through frontier, so that the local areas are popular, and serious threats are formed on the sanitary safety of animals in China, especially the sanitary safety of small ruminants, therefore, the establishment of a small ruminants diagnosis method with high sensitivity and strong specificity is particularly urgent.
The PPRV belongs to the genus morbillivirus (Morbollivirus) of Paramyxoviridae (Paramyxoviriae), and other members of the same genus include Rinderpest virus (RPV), Canine Distemper Virus (CDV), seal Pestivirus (PDV), Dolphia virus (DDV), bovine Measles Virus (MVKI), human Measles Virus (MV), and the like. The genome structure of PPRV is single negative strand, non-segmented RNA.
The diagnostic method of the peste des petits ruminants mainly comprises virus separation and identification, antibody serology detection, antigen detection and the like. The antigen detection methods include Agar Gel Immunodiffusion (AGID), Countercurrent Immunoelectrophoresis (CIEP), indirect fluorescent antibody assay (IFAT), and the like.
At present, no effective method for treating peste des petits ruminants exists, and control can be performed only by adopting methods of vaccination, killing after epidemic situations occur and regular serum monitoring. Therefore, serological diagnosis of the disease and evaluation and monitoring of vaccine immune effect are important.
The peste des petits ruminants virus antibody detection methods recommended by the world animal health organization mainly include Virus Neutralization Test (VNT) and enzyme-linked immunoassay (ELISA). The detection result of the virus neutralization test method is accurate and is a gold standard for detecting the peste des petits ruminants virus, but the method has long detection time and is not suitable for detecting a large number of samples. In contrast, enzyme-linked immunoassay has high specificity and sensitivity, has a shorter detection time than virus neutralization tests, and is suitable for detecting a large number of samples, and therefore, is widely applied to the detection of peste des petits ruminants virus antibodies.
The enzyme-linked immunoassay method for detecting the peste des petits ruminants virus antibody mainly comprises competitive enzyme-linked immunoassay (c-ELISA), blocking enzyme-linked immunoassay (b-ELISA) and indirect enzyme-linked immunoassay (indirect ELISA). The c-ELISA and the b-ELISA have higher specificity and sensitivity, and are generally accepted methods for detecting peste des petits ruminants virus antibodies in clinic, for example, the c-ELISA method is adopted by a peste des petits ruminants diagnostic kit of a French BIRAD laboratory which is commonly used internationally. However, both c-ELISA and b-ELISA need monoclonal antibody, which results in greatly increased detection cost; furthermore, c-ELISA and b-ELISA are cumbersome to operate, long in detection time (although already shortened relative to VNT), and complex in criteria. On the other hand, the conventional indirect ELISA detects antibodies in serum using intact proteins (e.g., H protein, N protein, F protein, etc.) or recombinant proteins derived from Peste des petits ruminants virus as a coating antigen at a cost lower than that of c-ELISA and b-ELISA; however, since this method uses the intact protein as an antigen, erroneous recognition and non-specific recognition of the antibody easily occur, and thus, its specificity and sensitivity are inferior to those of c-ELISA and b-ELISA.
Therefore, there is a need to develop a diagnostic kit for Peste des petits ruminants that is low in detection cost, short in detection time, simple and convenient to operate, and high in specificity and sensitivity.
Disclosure of Invention
In view of the problems in the prior art, the present invention aims to provide a diagnostic kit for Peste des petits ruminants, which has the advantages of low detection cost, short detection time, simple operation, high specificity and sensitivity, and a polypeptide or a polypeptide combination capable of being used for preparing the kit.
The indirect ELISA method based on epitope polypeptides uses epitope polypeptides (a single polypeptide of around 20 amino acids usually contains only one epitope) as the coating antigen. The inventor finds that: the sensitivity of the method is low, and the sensitivity of a single polypeptide generally does not exceed 50%; the polypeptide with high sensitivity also has high false positive rate, namely low specificity. If the specificity and the sensitivity of detection can be improved simultaneously in a certain way, the defects of the traditional indirect ELISA can be overcome, and a diagnostic kit of peste des petits ruminants with the specificity and the sensitivity which are comparable to those of c-ELISA and b-ELISA and even higher is developed.
The present inventors have conducted intensive studies to solve the above-mentioned problems and as a result, have found the following polypeptide combination 1. When at least any one of the following polypeptide combinations 1 is used as an index to respond to a biological sample of biological origin of a subject, Peste des petits ruminants can be diagnosed with a sensitivity of 92.2% and a specificity of 93.5%, and is completely comparable to the c-ELISA method and the b-ELISA method.
Accordingly, the present invention comprises:
1. a diagnostic kit for Peste des petits ruminants, comprising a substrate, and the following polypeptide combination 1 independently immobilized on the substrate;
polypeptide combination 1
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, and
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG.
2. The diagnostic kit for Peste des petits ruminants according to item 1, which is used for diagnosing whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine by detecting the presence or absence of antibodies (IgG) against Peste des petits ruminants virus in a biological sample derived from the subject organism.
3. The diagnostic kit for Peste des petits ruminants according to item 2, wherein the subject organism is a Peste des petits ruminants.
4. The diagnostic kit for Peste des petits ruminants according to item 2 or 3, wherein the subject organism is a goat or a sheep.
5. The diagnostic kit for Peste des petits ruminants according to any one of items 2 to 4, wherein the biological sample is whole blood, plasma or serum.
6. The application of the polypeptide combination 1 in preparing a diagnostic kit for peste des petits ruminants;
polypeptide combination 1
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, and
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG.
7. The use according to item 6, wherein the Peste des petits ruminants diagnostic kit is used for diagnosing whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine by detecting the presence or absence of antibodies (IgG) against Peste des petits ruminants virus in a biological sample of biological origin of the subject.
8. The use of item 7, wherein the subject organism is a small ruminant.
9. The use according to item 7 or 8, wherein the subject organism is a goat or a sheep.
10. The use according to any one of claims 7 to 9, wherein the biological sample is whole blood, plasma or serum.
The polypeptide and the kit can be used for detecting whether an antibody (IgG) resisting the peste des petits ruminants virus exists in a biological sample of a biological source of a subject. In general, antibodies against Peste des petits ruminants virus (IgG) in a biological sample are produced by infection of a subject organism with Peste des petits ruminants virus or immunization with Peste des petits ruminants vaccine, and thus the polypeptides and kits described above can be used to diagnose whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine.
Detailed description of the invention
First, the present invention provides the following polypeptide combination 1:
polypeptide combination 1
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, and
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG.
In contrast to the typical sensitivity of no more than 50% for a single polypeptide in an indirect ELISA method based on epitope polypeptides, peste des petits ruminants can be diagnosed with a sensitivity of 92.2% and a specificity of 93.5% using as an indicator at least any one of the polypeptide combinations 1 that responds to a biological sample of biological origin of a subject.
In the present specification, sensitivity means: among positive samples confirmed by the "gold standard" method, the proportion of positive samples determined by other methods was determined. The specificity refers to: among negative samples confirmed by the "gold standard" method, the proportion of negative samples was determined by other methods. For the detection of peste des petits ruminants virus antibodies, the "gold standard" in the art is the virus neutralization assay (VNT).
The polypeptide combination can be used as a detection probe for preparing a kit for detecting whether an antibody (IgG) resisting peste des petits ruminants virus exists in a biological sample of a biological source of a subject. In general, antibodies against Peste des petits ruminants virus (IgG) in a biological sample are produced by infection of a subject organism with Peste des petits ruminants virus or immunization with Peste des petits ruminants vaccine, and thus the polypeptide combinations and kits described above can be used to diagnose whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine.
Therefore, the present invention also provides a diagnostic kit for Peste des petits ruminants, which comprises a substrate, and the above-mentioned polypeptide combination 1 independently attached to the substrate.
In the present specification, the substrate is usually a solid, and may be one or more, but preferably one, that is, all the polypeptides are independently attached to the same substrate. In the present invention, the substrate is not particularly limited as long as it is a solid or insoluble material carrier. The attachment of the polypeptide to the substrate can be performed using methods known to those skilled in the art for attachment of polypeptides to solid materials.
In the present specification, the subject organism is preferably a small ruminant, more preferably a goat or sheep.
In the present specification, the biological sample may be whole blood, plasma or serum.
In the case of diagnosing Peste des petits ruminants using the above-described kit, when any one or more of the polypeptides in the polypeptide combination 1 responds to a biological sample of biological origin of a subject, it is judged that the subject organism has been infected with Peste des petits ruminants virus or that the Peste des petits ruminants vaccine is immunized (i.e., positive); otherwise, the subject organism is determined not to be infected with peste des petits ruminants virus or immunized with peste des petits ruminants vaccine (i.e., negative).
In the present specification, "response" means: a signal-to-noise ratio (SNR) greater than or equal to 2, wherein signal-to-noise ratio ═ (polypeptide dot signal value-negative control dot signal value)/negative control dot signal value.
Examples
1. Preparation and validation of Polypeptides
SEQ ID NO: 1-6 were synthesized by Gill Biochemical (Shanghai) Co., Ltd, and confirmed by mass spectrometry. Wherein the content of the first and second substances,
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE, respectively;
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA, respectively;
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL, respectively;
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS, respectively;
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, respectively;
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG are provided.
2. Preparation of kit (polypeptide chip) 1
Kit 1
The polypeptide chip is prepared by mixing SEQ ID NO: 1-6 polypeptide solutions are respectively spotted on a solid support material, namely a '0 + X' membrane (iPDMS membrane), to prepare the polypeptide-based composite membrane (simultaneously, one goat IgG is spotted as a positive quality control point and one PB point is spotted as a negative quality control point). The "0 + X" film is a material obtained by adding an initiator having an olefin end and initiating polymerization reaction on the surface to a polydimethylsiloxane material and then fixing the initiator to the three-dimensional structure of the polydimethylsiloxane by thermal crosslinking (silicon hydrogen bonding). The manufacturing process can be seen in international publication WO 2014/044184.
3. Detection with a kit
Placing the polypeptide chip at room temperature for 20min, observing the surface of the chip with naked eyes, eliminating defective polypeptide chips, determining the correct direction of the polypeptide chip, clamping the polypeptide chip in a convex groove, numbering the chips according to the amount of serum, then filling TBST (0.4M Tris-HCl, 2.74M NaCl, 2% Tween20, pH7.2 +/-0.2) in qualified polypeptide chips, placing at room temperature for 2-4min, checking whether leakage exists or not, and discarding the leaked polypeptide chips. Filling up the vacant polypeptide chip, the operation is the same as above. Clamping qualified polypeptide chips on the convex groove, using TBST to rinse every 8 chips in a group for 2 times, using a spray can to rinse, enabling one chip to enter and exit from the hole to form flow, finally slightly beating the gauze, and taking a cover to spin-dry one by one, but keeping the surfaces of the polypeptide chips wet for later use.
Serum is diluted 50 times (5 mul serum sample +245 mul serum diluent) in a super clean bench to be numbered respectively, the serial numbers of the chip and the serum are uniformly mixed by shaking, the chip is loaded on a rinsed chip with 200 mul/hole to avoid generating bubbles, 200 mul diluted serum is added, the temperature is room temperature, the shaking table is 150rpm, and the incubation is carried out for 30 min.
Discarding the solution, rinsing 4 times (same method as above), spin-drying, adding secondary antibody (rabbit anti-goat IgG), incubating at room temperature and 150rpm of a shaker for 30 min.
Discarding the solution, discarding the cover, rinsing for 4 times, spin-drying, adding 20 μ l/well of luminescent solution (Thermo, Prod #37074) per 8 chips, and exposing for 2 min. Data were collected using GenePix pro 6.0.
For each serum, each polypeptide in the kit was counted for response (i.e., signal-to-noise ratio (SNR) of 2 or more) and judged.
For the above kit 1, when SEQ ID NO: 1-6, if any one or more than one of the polypeptides has a response, determining that the peste des petits ruminants is positive; otherwise, the result is judged to be negative.
Wherein, the signal-to-noise ratio is (polypeptide dot signal value-negative control dot signal value)/negative control dot signal value. The polypeptide dot signal value refers to the chemiluminescence intensity value of the polypeptide dot read by software, and the negative control dot signal value refers to the chemiluminescence intensity value of the negative control dot read by software.
755 goat and sheep serum samples from different regions of china were respectively detected by using the kit prepared in step 2 (step 3 above) and the virus neutralization test (VNT, according to the method described in OIE (2010) peste des petits ruminants virus neutralization test), and the detection results are shown below.
TABLE 1
Sensitivity 368/399 × 100%
Specificity 333/356 ═ 93.5%
As can be seen from the above, the sensitivity and specificity of kit 1 were both above 90% (and verified by VNT method, not by control kit method), which is comparable to the kits using c-ELISA method or b-ELISA method.
Sequence listing
<110> China institute for veterinary drug inspection
Luoyang Zhongke Biochip Technology Co.,Ltd.
<120> Peste des petits ruminants diagnostic kit
<130> PB00108
<141> 2018-04-24
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Ser Ala Glu Ala Leu Phe Arg Leu Gln Ala Met Ala Lys Ile Leu Glu
1 5 10 15
Asp Gln Glu Glu
20
<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Ser Ser Gln Asn Pro Arg Glu Ala Gln Arg Ser Ala Glu Ala Leu Phe
1 5 10 15
Arg Leu Gln Ala
20
<210> 3
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Leu Lys Pro Asp Leu Thr Gly Thr Ser Lys Ser Tyr Val Arg Ser Leu
1 5 10 15
<210> 4
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Val Ala Thr Ala Ala Gln Ile Thr Ala Gly Val Ala Leu His Gln Ser
1 5 10 15
Leu Met Asn Ser
20
<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Thr Gly Asp Glu Arg Thr Val Arg Gly Thr Gly Pro Arg Gln Ala Gln
1 5 10 15
Val Ser Phe Leu
20
<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Cys Cys Cys Lys Gly Arg Cys Arg Asn Lys Glu Ile Pro Ala Ser Lys
1 5 10 15
Ile Asn Pro Gly
20
Claims (6)
1. A polypeptide combination 1 consisting of SEQ ID NO: 1 to 6, wherein,
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE, respectively;
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA, respectively;
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL, respectively;
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS, respectively;
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, respectively;
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG are provided.
2. A peste des petits ruminants diagnostic kit, comprising:
the polypeptide combination of claim 1, wherein,
the polypeptide combination is used for being fixed on a substrate, and the polypeptide combination and the substrate are jointly made into a peste des petits ruminants diagnostic kit which is used for diagnosing whether a subject organism is infected by peste des petits ruminants virus or is immunized by peste des petits ruminants vaccine by detecting whether IgG antibody resisting the peste des petits ruminants virus exists in a biological sample of the subject organism.
3. The application of the polypeptide combination 1 in preparing a diagnostic kit for peste des petits ruminants;
polypeptide combination 1
SEQ ID NO: 1 is N50: SAEALFRLQAMAKILEDQEE in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 2 is N49: SSQNPREAQRSAEALFRLQA in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 3 is F54: LKPDLTGTSKSYVRSL in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 4 is F13: VATAAQITAGVALHQSLMNS in a pharmaceutically acceptable carrier or carrier, wherein,
SEQ ID NO: 5 is N41: TGDERTVRGTGPRQAQVSFL, and
SEQ ID NO: 6 is F52: CCCKGRCRNKEIPASKINPG.
4. The use according to claim 3, wherein the Peste des petits ruminants diagnostic kit is used for diagnosing whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine by detecting the presence or absence of IgG antibodies against Peste des petits ruminants virus in a biological sample of biological origin of the subject.
5. The use of claim 4, wherein the subject organism is a goat or sheep.
6. Use according to claim 4, wherein the biological sample is whole blood, plasma or serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810480848.7A CN110498845B (en) | 2018-05-18 | 2018-05-18 | Peste des petits ruminants diagnostic kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810480848.7A CN110498845B (en) | 2018-05-18 | 2018-05-18 | Peste des petits ruminants diagnostic kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110498845A CN110498845A (en) | 2019-11-26 |
| CN110498845B true CN110498845B (en) | 2021-03-09 |
Family
ID=68585157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810480848.7A Active CN110498845B (en) | 2018-05-18 | 2018-05-18 | Peste des petits ruminants diagnostic kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110498845B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113671182B (en) * | 2020-05-13 | 2023-11-28 | 洛阳中科生物芯片技术有限公司 | Antibody joint inspection kit for porcine pseudorabies virus gD and gE proteins and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014044184A1 (en) * | 2012-09-21 | 2014-03-27 | 苏州偲聚生物材料有限公司 | Protein for detecting type 1 diabetes mellitus and partial peptide thereof |
| CN107098979A (en) * | 2017-06-22 | 2017-08-29 | 中国动物疫病预防控制中心 | PPR virus H F fusion proteins and its relevant biological material and application |
-
2018
- 2018-05-18 CN CN201810480848.7A patent/CN110498845B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014044184A1 (en) * | 2012-09-21 | 2014-03-27 | 苏州偲聚生物材料有限公司 | Protein for detecting type 1 diabetes mellitus and partial peptide thereof |
| CN107098979A (en) * | 2017-06-22 | 2017-08-29 | 中国动物疫病预防控制中心 | PPR virus H F fusion proteins and its relevant biological material and application |
Non-Patent Citations (2)
| Title |
|---|
| Interference in the vaccination of cattle against rinderpest virus by antibodies against peste des petits ruminants (PPR) virus;E. Couacy-Hymann 等;《Vaccine》;20060615;全文 * |
| 小反刍兽疫病毒H和F蛋白多抗原表位的表达及其反应原性;石晓妮 等;《中国兽医科学》;20110520;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110498845A (en) | 2019-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111856027B (en) | New coronavirus antibody detection kit suitable for examination of patients without obvious symptoms | |
| CN108761077A (en) | Poultry diease viral disease protein chip antibody assay kit and its preparation method and application | |
| CN110240635B (en) | Polypeptide for detecting newcastle disease virus antibody and ELISA detection kit thereof | |
| CN113321715A (en) | Novel coronavirus antigen and detection use thereof | |
| CN110498845B (en) | Peste des petits ruminants diagnostic kit | |
| CN110498844B (en) | Peste des petits ruminants diagnostic kit | |
| CN110178031A (en) | The determination of serology of zika virus infection | |
| CN108956986B (en) | Newcastle disease virus antibody detection kit | |
| CN110501505B (en) | Peste des petits ruminants diagnostic kit | |
| CN112213493B (en) | Peste des petits ruminants detection kit capable of being used for distinguishing vaccine immunity from natural infection | |
| CN111537713B (en) | Peste des petits ruminants virus antibody detection kit | |
| AU2004273076A1 (en) | Method and device for detecting feline immunodeficiency virus | |
| JP6357425B2 (en) | Interfering peptide and method for detecting microorganisms | |
| CN110498842B (en) | Peste des petits ruminants diagnostic kit | |
| CN110488010B (en) | Newcastle disease virus antibody detection kit | |
| CN110488011B (en) | Newcastle disease virus antibody detection kit | |
| CN110488017B (en) | Newcastle disease virus antibody detection kit | |
| CN110498843B (en) | Peste des petits ruminants diagnostic kit | |
| KR20100031369A (en) | Rapid diagnostic kit of hemorrhagic fever with renal syndrome detecting specific igm and igg using nucleocapsid protein derived from soochong virus | |
| CN108717124A (en) | Newcastle disease virus antibody assay kit | |
| CN108693352B (en) | Newcastle disease virus antibody detection kit | |
| CN110531079B (en) | Newcastle disease virus antibody detection kit | |
| CN112552381B (en) | Antigenic peptide of rat coronavirus and application thereof | |
| CN110531080B (en) | Newcastle disease virus antibody detection kit | |
| CN110531081B (en) | Newcastle disease virus antibody detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |